RxDoctor Payments Data

Richard Stark, MD

Internal Medicine · Boone, NCNPI 1023104049

Payments from drug & device makers

$857in general payments, 2019–2025

Across 49 payments — averaging $17.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$212
  • Novo Nordisk$205
  • Lilly USA, LLC$73
  • GSK$72
  • AstraZeneca$57
  • Otsuka America Pharmaceutical, Inc.$49
  • plus $189 from 8 others

What the payments were for

  • Food & beverage$857100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$857 in reported general payments places this provider in the 70th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$147,122
Medicare patients
519
Services billed
2,038

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban317$266,420
JardianceEmpagliflozin103$120,386
OzempicSemaglutide50$62,940
XareltoRivaroxaban47$47,894
JanuviaSitagliptin Phosphate28$29,931
TrulicityDulaglutide29$27,923
LinzessLinaclotide28$20,876
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$19,327
Lantus SolostarInsulin Glargine,hum.Rec.Anlog105$16,937
MounjaroTirzepatide16$16,465
Spiriva HandihalerTiotropium Bromide12$14,979
Tresiba Flextouch U-200Insulin Degludec14$14,490
FarxigaDapagliflozin Propanediol25$14,474
Nucynta ErTapentadol Hcl12$14,274
Synjardy XrEmpagliflozin/Metformin Hcl13$13,940

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Prempro$212$269,404330 claims
Novo NordiskOzempic$205$62,94050 claims
Lilly USA, LLCTrulicity, Mounjaro$73$44,38845 claims
AbbVieLinzess, Synthroid$14$30,259145 claims
GSKTrelegy Ellipta, Breo Ellipta$72$27,11832 claims
AstraZenecaFarxiga, Symbicort$57$25,22552 claims
Sanofi-aventis U.S. LLCLantus$16$4,26816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Boone

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →